Sangamo Therapeutics (NASDAQ:SGMO) Shares Pass Above Two Hundred Day Moving Average of $0.66

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.66 and traded as high as $0.77. Sangamo Therapeutics shares last traded at $0.72, with a volume of 3,481,646 shares trading hands.

Analyst Upgrades and Downgrades

SGMO has been the subject of a number of recent analyst reports. StockNews.com began coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Sangamo Therapeutics in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Sangamo Therapeutics has an average rating of “Hold” and a consensus price target of $2.67.

Sangamo Therapeutics Stock Down 3.8 %

The business has a 50-day simple moving average of $0.68 and a two-hundred day simple moving average of $0.66. The stock has a market capitalization of $150.03 million, a price-to-earnings ratio of -0.39 and a beta of 1.23.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. On average, analysts forecast that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System boosted its holdings in Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 23,650 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth $89,000. Marshall Wace LLP grew its holdings in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the first quarter worth $331,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.